Comparative Pharmacology
Head-to-head clinical analysis: AK FLUOR 10 versus BLUDIGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AK FLUOR 10 versus BLUDIGO.
AK-FLUOR 10% vs BLUDIGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorescein sodium is a diagnostic dye that absorbs light in the blue spectrum (465-490 nm) and emits green-yellow fluorescence (520-530 nm). It is used to visualize blood flow, detect corneal abrasions, and assess vascular integrity by highlighting areas of leakage or damage.
BLUDIGO is a selective inhibitor of the hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor, thereby suppressing the transcription of glioma-associated oncogene (GLI) family members and downstream target genes involved in cell proliferation and survival.
Intravenous injection: 5-10 mL (500-1000 mg fluorescein sodium) given rapidly over 4-5 seconds.
Intravenous (IV) 5 mg/kg every 8 hours, infused over 90 minutes on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 minutes in patients with normal renal function. This short half-life reflects rapid redistribution and renal clearance.
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Primarily renal (unchanged). Approximately 80-90% of an administered dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Primarily renal (70-80% unchanged) and biliary (15-20% as glucuronide conjugates); fecal excretion <5%.
Category C
Category C
Diagnostic Dye
Diagnostic Dye